Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Oxine-RY_SW01 in Systemic Sclerosis
NCT06489652Phase 1Not yet recruiting
- Sponsor
- Jiangsu Renocell Biotech
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, open-label, single-arm trial of 89zr-oxine-ry_sw01 in systemic sclerosis (SSc), sponsored by Jiangsu Renocell Biotech. Primary endpoints: Urine SUV value at 14 days and Fecal SUV value at 14 days. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
89zr-oxine-ry_sw01
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06489652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489652.